Spread | 0.22 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 51.21 |
Open | 50.95 |
1-Year Change | -12.23% |
Day's Range | 50.23 - 50.95 |
Globus Medical, Inc. is a medical device company. The Company is primarily focused on implants that promote healing in patients with musculoskeletal disorders. The Company group its products into two categories: Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are computer-assisted intelligent systems designed to improve a surgeon’s capabilities, and ultimately improve patient care and reduce radiation exposure for all involved. Its INR solutions include the ExcelsiusGPS platform, which is a robotic guidance and navigation system that supports minimally invasive and open procedures with screw and interbody spacer placement applications.
BRIEF: For the fiscal year ended 31 December 2021, Globus Medical Inc revenues increased 21% to $958.1M. Net income increased 46% to $149.2M. Revenues reflect Musculoskeletal Solutions products segment increase of 17% to $876.8M, Enabling Technologies products segment increase of 100% to $81.3M, United States segment increase of 23% to $819.6M, International segment increase of 11% to $138.5M.
Cls A Common stock $.001 Par 8/12, 500M auth., 62,503,441 issd., Insiders own approx. 86.70%. Cls B Common Stock 275M auth., 27,885,000 issd.